Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Christian Daniel Fankhauser; Jan Oldenburg; Peter Albers; Ferran Algaba; Carsten Bokemeyer; Joost L Boormans; Stefanie Fischer; Karim Fizazi; Hendrik Gremmels; Javier Mayor de Castro; Florian Janisch; Tim Muilwijk; Ricardo Leão; David Nicol; Nicola Nicolai; Torgrim Tandstad; M Pilar Laguna

doi:10.1016/j.eururo.2021.02.032

Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Christian Daniel Fankhauser
Jan Oldenburg
Peter Albers
Ferran Algaba
Carsten Bokemeyer
Joost L Boormans
Stefanie Fischer
Karim Fizazi
Hendrik Gremmels
Javier Mayor de Castro
Florian Janisch
Tim Muilwijk
Ricardo Leão
David Nicol
Nicola Nicolai
Torgrim Tandstad
M Pilar Laguna

Related Research units

Abstract

Men with metastatic germ cell tumors undergoing chemotherapy are at high risk of venous thromboembolic events and low risk of bleeding. A central venous-access device should be avoided whenever possible. Thromboprophylaxis may be prescribed after balancing the risks and benefits for each individual patient.

Bibliographical data

Original language	English
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2021.02.032
Publication status	Published - 07.2021

PubMed	33722419